The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis

Autor:	Marina Pontello Cristelli, Helio Tedesco Silva Junior, Daniel Wagner de Castro Lima Santos, Claudia Rosso Felipe, Geovana Basso, Jose O. Medina-Pestana, Juliana Mansur Siliano, Alexandra Nicolau Ferreira Brigido, Wilson Aguiar, Laila Almeida Viana, Suelen Bianca Stopa Martins
Rok vydání:	2018
Předmět:	Adult Graft Rejection Male 0301 basic medicine medicine.medical_specialty Basiliximab education Congenital cytomegalovirus infection Cytomegalovirus 030230 surgery Virus Replication Kidney transplant Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Serologic Tests Everolimus Prospective Studies Antilymphocyte Serum Retrospective Studies Transplantation business.industry Incidence TOR Serine-Threonine Kinases Incidence (epidemiology) virus diseases Middle Aged Viral Load medicine.disease Kidney Transplantation Tacrolimus Anti-thymocyte globulin Treatment Outcome 030104 developmental biology Infectious Diseases Cytomegalovirus Infections Kidney Failure Chronic Female business Viral load Immunosuppressive Agents medicine.drug
Zdroj:	Transplant Infectious Disease. 20:e12919
ISSN:	1398-2273
DOI:	10.1111/tid.12919
Popis:	BACKGROUND The use of mTOR inhibitors is associated with lower incidence of CMV infections but its effect on viral load has not been investigated. AIMS, MATERIALS AND METHODS This post-hoc analysis included data from 273 CMV seropositive kidney transplant recipients randomized to receive anti-thymocyte globulin and everolimus (rAGT/TAC/EVR, n = 81), basiliximab and everolimus (BAS/TAC/EVR, n = 97) or basiliximab and mycophenolate (BAS/TAC/MPS, n = 95). All patients received tacrolimus (TAC) and corticosteroids. Preemptive CMV therapy based on weekly pp65 antigenemia test was used during the first 6 months. Blinded weekly CMV DNAemia was compared among the groups. RESULTS The proportion of patients with undetectable CMV DNAemia (23.4% vs 56.7% vs 22.1%, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1071ab2affa4f4498842eacb1a41d1 https://doi.org/10.1111/tid.12919 Zobrazit plný text záznamu Plný text